The journal retracts the article “Environmental risk assessment of mixture of COVID-19 treating pharmaceutical drugs in zebrafish early life stage (Danio rerio)” [1], cited above.
Following publication, concerns were brought to the attention of the Editorial Office regarding the duplication of images contained within this publication [1].
Adhering to our complaints procedure, an investigation was conducted by the Editorial Office and the Editorial Board that confirmed the duplication of a number of panels contained within Figures 1 and 3 presenting different experimental conditions. Following discussions with the authors, the Editorial Board were unable accept the explanation provided or verify the validity of the above-mentioned images. Consequently, the Editorial Board has lost confidence in the reliability of the findings and decided to retract this publication [1], as per MDPI’s retraction policy (https://www.mdpi.com/ethics#_bookmark30).
This retraction was approved by the Editor-in Chief of the journal Toxics.
The authors did not agree to this retraction.
Reference
- Di Paola, D.; Abbate, J.M.; Iaria, C.; Cordaro, M.; Crupi, R.; Siracusa, R.; D’Amico, R.; Fusco, R.; Impellizzeri, D.; Cuzzocrea, S.; et al. RETRACTED: Environmental Risk Assessment of Dexamethasone Sodium Phosphate and Tocilizumab Mixture in Zebrafish Early Life Stage (Danio rerio). Toxics 2022, 10, 279. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).